Apogee Therapeutics, Inc. APGE Income Statement
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| $214.71M+27.9% | $167.87M+145% | $68.42M— | ||
| $70.88M+44.6% | $49.01M+99.4% | $24.58M— | ||
| $285.6M+31.7% | $216.87M+133% | $93M— | ||
| $285.6M+31.7% | $216.87M+133% | $93M— | ||
| -$285.6M-31.7% | -$216.87M-133% | -$93M— | ||
| $30.03M-13.6% | $34.74M+285% | $9.02M— | ||
| $30.03M-13.6% | $34.74M+285% | $9.02M— | ||
| -$255.57M-40.3% | -$182.13M-117% | -$83.99M— | ||
| $278K+1,444% | $18K— | $0— | ||
| -$255.84M-40.5% | -$182.15M-117% | -$83.99M-28.1% | ||
| -$4.22-28.3% | -$3.29+53.8% | -$7.12— | ||
| -$4.22-28.3% | -$3.29+53.8% | -$7.12— | ||
| 236.1M+8.0% | 218.7M+187% | 76.2M— | ||
| 236.1M+8.0% | 218.7M+187% | 76.2M— | ||
| $30.03M-13.6% | $34.74M+285% | $9.02M— | ||
| -$285.6M-31.7% | -$216.87M-133% | -$93M— | ||
| -$284.18M-31.2% | -$216.68M— | —— | ||
| -$284.18M-31.2% | -$216.68M— | —— | ||
| -$285.6M-31.7% | -$216.87M-133% | -$93M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Apogee Therapeutics, Inc. profitable?
- Apogee Therapeutics, Inc. is not currently profitable: it reported a net loss of $274.6M over the trailing twelve months.
- What is Apogee Therapeutics, Inc.'s earnings per share?
- Apogee Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.
- Where does Apogee Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.